Register for updates

Stay in touch and receive the latest news on TROGARZO™.

*Required field.

Please enter your first name
Please enter your last name
Please enter valid email address
Please enter your telephone number including area code
Please enter your first name
Please enter your city
Please enter your state
Please enter valid ZIP code

By providing the above information, you agree to allow Theratechnologies Inc. to provide you with information relating to Theratechnologies' products. The information you submit will be governed by our Privacy Policy.

For more information

Talk to your Theratechnologies representative
OR
Call the THERA patient support™ program at 1-833-238-4372

Thera patient support logo

Personalized service to help patients make the most of their therapy.

The THERA patient support™ program provides guidance and support during treatment with TROGARZO™. From navigating insurance issues to answering common therapy-related questions, our knowledgeable and attentive team is there to help.

Our experienced Patient care coordinators can help with:
  • Coordinating appropriate insurance and coverage options.
  • Identifying Specialty Pharmacy or Infusion Service Providers in a patient’s insurance network, so they can receive convenient infusions.
  • Helping patients get ready for therapy with educational materials and support.

+
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
  • Immune Reconstitution Inflammatory Syndrome (IRIS) has been reported in one patient treated with TROGARZO™ in combination with other antiretrovirals. During the initial phase of combination antiretroviral therapies, patients whose immune systems respond may develop an inflammatory response to indolent or residual opportunistic infections, which may necessitate further evaluation and treatment.
Adverse Reactions
  • The most common adverse reactions (reported in ≥5.0% of patients) were diarrhea (8%), dizziness (8%), nausea (5%) and rash (5%).
  • Most (90%) of the adverse reactions reported were mild or moderate in severity. Two subjects experienced severe adverse reactions: one subject had a severe rash and one subject developed IRIS manifested as an exacerbation of progressive multifocal leukoencephalopathy.
Use in Specific Populations
  • Pregnancy: No adequate human data are available to establish whether or not TROGARZO™ poses a risk to pregnancy outcomes. Monoclonal antibodies, such as ibalizumab-uiyk, are transported across the placenta as pregnancy progresses; therefore, ibalizumab-uiyk has the potential to be transmitted from the mother to the developing fetus.
  • Lactation: No data are available regarding the presence of TROGARZO™ in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for HIV-1 transmission, instruct mothers not to breastfeed if they are receiving TROGARZO™.

To report suspected adverse reactions, contact THERA patient support™ (1-833-238-4372) or the FDA (1-800-FDA-1088 or fda.gov/medwatch).

Please see full Prescribing Information for TROGARZO™.

Privacy Policy | Legal Statement
Theratechnologies logo